1st-of-its-kind Parkinson's treatment may slow aggressive disease, trial hints

A first-of-its kind antibody treatment may slow the progression of movement problems in some people with Parkinson's disease , early clinical trial data suggest.

Now, there's evidence that prasinezumab may work, at least for some people. An analysis from an ongoing, midstage clinical trial suggests prasinezumab may slow the signs of motor dysfunction in people with rapidly progressing forms of PD. The results were published Monday in the journal Nature Medicine.The analysis took a closer look at 316 participants from the clinical trial.

By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.They used standard tools to measure how quickly the participants' movement symptoms worsened and found that patients treated with prasinezumab fared better than those treated with placebo. This is a hypothesis, as the researchers didn't directly track the alpha-synuclein levels in people's brains, Vinata Vedam-Mai, a neurology researcher at the University of Florida Health, told New Scientist. Thus, they can't say for sure that the antibody cleared away the protein.

Although prasinezumab didn't seem to work for people with slower PD, it may be that a longer trial period is needed to spot changes in these individuals, the researchers noted in their report.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

'Very concerning': Microplastics can accumulate in cancer cells and may help them spread, study hintsSneha Khedkar is a biologist-turned-freelance-science-journalist from India. She holds a master's degree in biochemistry and a bachelor's degree in microbiology and biochemistry. After her master's, she worked as a research fellow for four years, studying stem cell biology.
Source: LiveScience - 🏆 538. / 51 Read more »

Cholesterol-gobbling gut bacteria could protect against heart diseaseSneha Khedkar is a biologist-turned-freelance-science-journalist from India. She holds a master's degree in biochemistry and a bachelor's degree in microbiology and biochemistry. After her master's, she worked as a research fellow for four years, studying stem cell biology.
Source: LiveScience - 🏆 538. / 51 Read more »

Small Study Suggests Ozempic Relative May Slow Parkinson'sCould a medication similar to the blockbuster weight-loss drugs Ozempic and Wegovy slow the ravages of Parkinson's disease?
Source: MedicineNet - 🏆 575. / 51 Read more »